TSPO and myeloid sarcoma: TSPO agent utility, however, extends beyond MS because similar pathophysiologic changes are also seen in ALS, Psychiatric disorders, Alzheimer’s, Parkinson’s, and Huntington’s disease, as well as colitis [26,27].